Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in the Development of Novel Oncology Treatments
OXFORD, England & HOUSTON, Texas–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) and the University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align Exscientia’s patient-centric artificial intelligence (AI) capabilities with MD Anderson’s drug discovery and development expertise to advance new small molecule oncology therapies.
The research collaboration will use Exscientia’s precision medicine platform to identify novel cell-intrinsic small molecule anti-cancer compounds based on jointly identified therapeutic targets. Promising candidates will progress to further development with the team at MD Anderson’s Therapeutics Discovery division. The collaborators anticipate that successful target discovery programs could be advanced into proof-of-concept clinical trials at MD Anderson.
“We are committed to developing the next generation of oncology treatments that can deliver significant benefits and improve the lives of our patients,” said Philip Jones, Ph.D., vice president of Therapeutics Discovery and director of the Institute for Applied Cancer Science (IACS) at MD Anderson. “This collaboration leverages Exscientia’s AI-based precision medicine platform, the strength of MD Anderson’s drug discovery and development engine, and the expertise of our clinical research teams. Our ultimate goal is to reduce the time we spend on drug development and accelerate the introduction of new targeted therapies into the clinic. »
Exscientia will collaborate with the team at IACS, a drug discovery engine focused on the development of new small molecule therapies. IACS is a central component of MD Anderson’s Therapeutics Discovery division, an integrated team of researchers, physicians and drug development experts working to advance impactful new therapies.
“We are extremely proud to work alongside MD Anderson to leverage our AI-based platform for the discovery of next-generation cancer treatments. Artificial intelligence has opened up new possibilities in cancer research, allowing us to use multi-omics deep learning within our precision medicine platform to test potential drug candidates in tissue models of patients of Exscientia,” said Professor Andrew Hopkins, D.Phil., Founder and Chief Executive Officer of Exscientia. “Furthermore, our platform has the potential to stratify patients even at the early stage of discovery, allowing us to efficiently design drug candidates that are most likely to impact people with cancer.”
Under the terms of the agreement, Exscientia and MD Anderson will jointly contribute and support each designated program moving forward.
MD Anderson has an institutional conflict of interest with Exscientia, and that relationship will be managed in accordance with an MD Anderson Institutional Conflict of Interest Management and Monitoring Plan.
Exscientia is an AI-driven pharmaceutical company committed to discovering, designing and developing the best possible medicines in the fastest and most efficient way. Exscientia has developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to advance AI-engineered small molecules as part of clinical. Our internal pipeline focuses on leveraging our precision medicine platform in oncology, while our partnership pipeline expands our approach to other therapeutic areas. By pioneering a new approach to drug creation, we believe the best ideas in science can quickly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, UK), with offices in Vienna (Austria), Dundee (Scotland, UK), Boston (Massachusetts, USA), Miami (Florida, USA), Cambridge (England, United Kingdom) and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
About MD Anderson
The MD Anderson Cancer Center at the University of Texas at Houston is one of the world’s most respected centers focused on cancer patient care, research, education, and prevention. The institution’s sole mission is to end cancer for patients and their families worldwide. MD Anderson is one of 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is #1 for cancer in U.S. News & World Report’s “Best Hospitals” ranking and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives an NCI Cancer Center Support Grant from the National Institutes of Health (P30 CA016672).
Exscientia Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to progress in the discovery and development of candidate molecules, as well as the timing, progress and data from clinical trials. testing of Exscientia’s product candidates and Exscientia’s expectations regarding its revenue and cash flow forecasts. Any statement describing Exscientia’s objectives, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. These statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic may have on the Company’s business, including the scope, progress and expanding Exscientia’s product development efforts; the initiation, scope and progress of planned and ongoing preclinical studies and clinical trials of Exscientia and its partners and their offshoots for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercializing safe and effective product candidates for use in human therapeutics; and the effort to build a business around these product candidates. In light of these risks and uncertainties, and other risks and uncertainties described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC ) on March 23, 2022 (File No. 001-40850), and other documents filed by Exscientia with the SEC from time to time (which are available at https://www.sec.gov/), events and the circumstances discussed in these forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, such statements are based solely on facts and factors currently known to the Company. Accordingly, you are cautioned not to rely on these forward-looking statements.